NurExone Advances ExoPTEN for Clinical Manufacturing
TORONTO and HAIFA, Israel — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90), a cutting-edge biotechnology company dedicated to developing exosome-based therapies, is taking significant strides in preparing for its clinical readiness strategy. The company is currently evaluating potential manufacturing partners to establish small-scale GMP-based production of its lead therapeutic candidate, ExoPTEN. This move is aimed at supporting the drug's entry into a First-in-Human Use program, pending necessary regulatory approvals.
CEO's Vision for ExoPTEN
Dr. Lior Shaltiel, the Chief Executive Officer of NurExone, emphasizes the unique capabilities of ExoPTEN. He states, “ExoPTEN combines potent exosomes with a targeted siRNA, creating a powerful synergy. By producing small clinical grade batches, we are strategically positioning ourselves to prepare for the eventual submission for First-in-Human use, contingent on regulatory endorsement.” He further elaborates that ExoPTEN aims to address acute spinal cord injuries and optic nerve damage, though a definitive priority for the type of indication has not yet been established.
Scientific Progress Strengthens Confidence
Simultaneously, NurExone is excited to share promising new scientific data that enhances confidence in its exosome platform, particularly as the company steers towards human clinical studies. This data showcases the enhanced biological activity of NurExone's exosomes, particularly when compared to existing commercial options, reaffirming their potential role in regenerative medicine.
Manufacturing Initiatives in Israel
NurExone is actively working with various Israeli production partners that specialize in advanced biologics and GMP-compliant systems. This initial phase of small-scale ExoPTEN manufacturing is foundational, laying the groundwork for a smooth transition to larger scale production in the United States in the future. Dr. Ina Sarel, Head of CMC, Quality and Regulatory Affairs, describes this as an essential step in reducing operational risks.
Key Developments in Exosome Potency
Recent analytical testing has revealed that NurExone's exosomes derived from human bone marrow mesenchymal stem cells exhibit significantly superior CD73-associated biological activity compared to commercially sourced exosome controls. CD73 is pivotal for tissue signaling and repair processes, making these findings integral for potential clinical applications.
Exosome Conversion Results
The results indicate that NurExone’s two manufacturing batches achieve statistically significant enhancements in adenosine monophosphate (AMP) to adenosine conversion rates per particle in comparison to industry standards. These findings not only validate the therapeutic potential of NurExone’s exosomes but also support their function as an effective delivery mechanism for the ExoPTEN product.
Strategic Engagement with Russo Partners
In an effort to bolster its communications strategy, NurExone has engaged Russo Partners LLC. Subject to approval from the TSX Venture Exchange, this New York-based strategic communications firm will provide consulting services for an initial period of two months, at a fixed fee of US$6,600. This partnership is aimed at enhancing NurExone's outreach and stakeholder engagement.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a prominent biotech firm listed on TSXV, OTCQB, and Frankfurt, dedicated to developing innovative exosome-based therapies targeting central nervous system injuries. The company's flagship product, ExoPTEN, has demonstrated compelling preclinical evidence supporting its clinical application for acute spinal cord and optic nerve ailment, addressing significant market opportunities. With regulatory approvals, including an Orphan Drug Designation, the company is poised to initiate clinical trials across key markets in North America and Europe.
Company Growth and Future Opportunities
NurExone’s operations also extend to the establishment of Exo-Top Inc., facilitating its growth strategy within North America. This strategic positioning underscores the company's commitment to leadership in the biopharmaceutical landscape.
Frequently Asked Questions
What is NurExone's primary focus?
NurExone focuses on developing exosome-based therapies specifically aimed at treating injuries to the central nervous system.
What is ExoPTEN?
ExoPTEN is NurExone's lead product, designed to address issues in acute spinal cord and optic nerve injuries through innovative exosome technology.
What stage is NurExone currently in?
NurExone is in the early stages of clinical readiness, assessing manufacturing options and preparing for regulatory submissions related to ExoPTEN.
Who is involved in the company’s strategic communication efforts?
NurExone has partnered with Russo Partners to enhance its communications strategy and stakeholder engagement initiatives.
How can investors contact NurExone for more information?
Investors can reach out via email at info@nurexone.com or call the company directly.
